JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB62170

Anti-Phospholamban (phospho S16 + T17) 抗体

Anti-Phospholamban (phospho S16 + T17) antibody

Be the first to review this product! Submit a review

|

(7 Publications)

Rabbit Polyclonal Phospholamban phospho S16 + T17 antibody. Suitable for ICC/IF and reacts with Rat samples. Cited in 7 publications. Immunogen corresponding to Synthetic Peptide within Human PLN pS16 + T17.

別名を表示する

PLB, PLN, Phospholamban, pln thr17, pln ser16

1 Images
Immunocytochemistry/ Immunofluorescence - Anti-Phospholamban (phospho S16 + T17) antibody (AB62170)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Phospholamban (phospho S16 + T17) antibody (AB62170)

Immunofluorescence analysis of HuvEc cells, using Phospholamban (phospho S16 + T17) antibody (ab62170) at 1/500 - 1/1000 dilution, in the presence (right panel) and absence (left panel) of immunising phosphopeptide.

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Rat

アプリケーション

ICC/IF

applications

免疫原

Synthetic Peptide within Human PLN pS16 + T17. The exact immunogen used to generate this antibody is proprietary information.

P26678

style
left-column

代替製品

Primary Antibodies

AB126174

Anti-Phospholamban antibody

Western blot - Anti-Phospholamban antibody (AB126174)

  • 4
  • 1
Primary Antibodies

AB92697

Anti-Phospholamban (phospho S16) antibody [EPR1911]

RabMAb|Recombinant

Western blot - Anti-Phospholamban (phospho S16) antibody [EPR1911] (AB92697)

  • 0
  • 0
Primary Antibodies

AB219626

Anti-Phospholamban antibody [EPR21897]

RabMAb|Recombinant|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Phospholamban antibody [EPR21897] (AB219626)

  • 4
  • 1
Primary Antibodies

AB234903

Anti-Phospholamban antibody [EPR21897] - BSA and Azide free

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Phospholamban antibody [EPR21897] - BSA and Azide free (AB234903)

  • 1
  • 1

組合せ製品

Primary Antibodies

AB3625

Anti-SERCA2 ATPase antibody

Western blot - Anti-SERCA2 ATPase antibody (AB3625)

  • 4
  • 6
Primary Antibodies

AB219626

Anti-Phospholamban antibody [EPR21897]

RabMAb|Recombinant|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Phospholamban antibody [EPR21897] (AB219626)

  • 4
  • 1
Primary Antibodies

AB177952

Anti-NCX1 antibody [EPR12739]

20ul selling size|RabMAb|Recombinant

Western blot - Anti-NCX1 antibody [EPR12739] (AB177952)

  • 3
  • 1
Primary Antibodies

AB302716

Anti-Ryanodine receptor 2/RYR-2 antibody [EPR26288-70]

BOND RX™ Validated|20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Ryanodine receptor 2/RYR-2 antibody [EPR26288-70] (AB302716)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Rat": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/500 - 1/1000", "ICCIF-species-notes": "<p></p>" } } }
style
left-column
style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Immunogen
精製に関する特記事項
Purified from rabbit antiserum by affinity chromatography using epitope specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
保管に関する情報
Stable for 12 months at -20°C
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Phospholamban abbreviated as PLN is an important regulatory protein in cardiac muscle cells often referred to interchangeably with its phosphorylated form phospho-phospholamban. This protein with a molecular mass of about 6 kDa is primarily expressed in cardiac and skeletal muscles. It functions mechanically by regulating the calcium pump (SERCA2a) in the sarcoplasmic reticulum modulating calcium uptake during muscle relaxation. In its unphosphorylated state phospholamban inhibits the activity of SERCA2a reducing calcium uptake and affecting muscle contractility.
Biological function summary

Phospholamban serves as an important mediator in the control of cardiac muscle contraction and relaxation. It is a component of the calcium cycling process within heart cells and associates directly with SERCA2a to form a regulatory complex. This association allows phospholamban to influence calcium homeostasis significantly affecting myocardial contractility and relaxation. Phosphorylation of phospholamban typically induced by beta-adrenergic signaling results in diminished interaction with SERCA2a enhancing calcium uptake into the sarcoplasmic reticulum.

Pathways

Several important pathways involve phospholamban including the adrenergic signaling pathway in cardiomyocytes and calcium signaling pathways. Phospholamban's role in these pathways is linked with proteins like SERCA2a and Protein Kinase A (PKA). PKA phosphorylates phospholamban an important step in the beta-adrenergic cascade that leads to increased heart muscle contractility. This phosphorylation event highlights phospholamban's participation in modulating cardiac output under sympathetic nervous system influence.

Phospholamban's regulation of calcium homeostasis connects it directly to conditions like heart failure and cardiomyopathy. In heart failure the dysregulation of phospholamban phosphorylation can lead to impaired cardiac function due to disrupted calcium cycling reducing cardiac output. Mutations in the phospholamban gene can lead to dilated cardiomyopathy a condition characterized by the enlargement and weakening of the heart muscle. These mutations affect the interaction with SERCA2a highlighting the role of phospholamban in maintaining cardiac muscle health.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Reversibly inhibits the activity of ATP2A2/SERCA2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+) (PubMed : 28890335). Binds preferentially to the ATP-bound E1 conformational form of ATP2A2 which predominates at low Ca(2+) concentrations during the diastolic phase of the cardiac cycle (By similarity). Inhibits ATP2A2 Ca(2+) affinity by disrupting its allosteric activation by ATP (By similarity). Modulates the contractility of the heart muscle in response to physiological stimuli via its effects on ATP2A2. Modulates calcium re-uptake during muscle relaxation and plays an important role in calcium homeostasis in the heart muscle. The degree of ATP2A2 inhibition depends on the oligomeric state of PLN. ATP2A2 inhibition is alleviated by PLN phosphorylation (By similarity). Also inhibits the activity of ATP2A3/SERCA3 (By similarity). Controls intracellular Ca(2+) levels in elongated spermatids and may play a role in germ cell differentiation (By similarity). In the thalamic reticular nucleus of the brain, plays a role in the regulation of sleep patterns and executive functioning (By similarity).
See full target information PLN pS16 + T17
style
left-column

文献 (7)

Recent publications for all applications. Explore the full list and refine your search

Biomedicines 13: PubMed41007781

2025

Prior Aerobic Exercise Training Fails to Confer Cardioprotection Under Varying Exercise Volumes in Early Post-Infarction Cardiac Remodeling in Female Rats.

Applications

Unspecified application

Species

Unspecified reactive species

André Rodrigues Lourenço Dias,Ednei Luiz Antonio,Helenita Antonia de Oliveira,Ighor Luiz Azevedo Teixeira,Larissa Emília Seibt,Andrey Jorge Serra

BMC cardiovascular disorders 24:197 PubMed38580957

2024

HAPLN1 knockdown inhibits heart failure development via activating the PKA signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Tao Yan,Shushuai Song,Wendong Sun,Yiping Ge

Redox biology 44:102016 PubMed34038814

2021

Histidine dipeptides are key regulators of excitation-contraction coupling in cardiac muscle: Evidence from a novel CARNS1 knockout rat model.

Applications

Unspecified application

Species

Unspecified reactive species

Lívia de Souza Gonçalves,Lucas Peixoto Sales,Tiemi Raquel Saito,Juliane Cruz Campos,Alan Lins Fernandes,José Natali,Leonardo Jensen,Alexandre Arnold,Lisley Ramalho,Luiz Roberto Grassmann Bechara,Marcos Vinicius Esteca,Isis Correa,Diogo Sant'Anna,Alexandre Ceroni,Lisete Compagno Michelini,Bruno Gualano,Walcy Teodoro,Victor Henrique Carvalho,Bianca Scigliano Vargas,Marisa Helena Gennari Medeiros,Igor Luchini Baptista,Maria Cláudia Irigoyen,Craig Sale,Julio Cesar Batista Ferreira,Guilherme Giannini Artioli

Experimental and therapeutic medicine 18:4631-4636 PubMed31798700

2019

Nkx2.5 insufficiency leads to atrial electrical remodeling through Wnt signaling in HL-1 cells.

Applications

Unspecified application

Species

Unspecified reactive species

Jingjing Chen,Shunen Xu,Wei Li,Lirong Wu,Long Wang,Yongkang Li,Wei Zhou

Physiological reports 7:e13972 PubMed30806037

2019

Exercise training reduces ventricular arrhythmias through restoring calcium handling and sympathetic tone in myocardial infarction mice.

Applications

Unspecified application

Species

Unspecified reactive species

Rujie Qin,Nobuyuki Murakoshi,DongZhu Xu,Kazuko Tajiri,Duo Feng,Endin N Stujanna,Saori Yonebayashi,Yoshimi Nakagawa,Hitoshi Shimano,Akihiko Nogami,Akira Koike,Kazutaka Aonuma,Masaki Ieda

Cardiovascular research 108:197-208 PubMed26378152

2015

LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.

Applications

Unspecified application

Species

Unspecified reactive species

Grace E Kim,Jenna L Ross,Chaoqin Xie,Kevin N Su,Vlad G Zaha,Xiaohong Wu,Monica Palmeri,Mohammed Ashraf,Joseph G Akar,Kerry S Russell,Fadi G Akar,Lawrence H Young

PloS one 8:e82552 PubMed24386101

2013

Sarcoplasmic phospholamban protein is involved in the mechanisms of postresuscitation myocardial dysfunction and the cardioprotective effect of nitrite during resuscitation.

Applications

WB

Species

Rat

Yu Huang,Qing He,Lei Zhan,Min Yang
View all publications
style
left-column
style
left-column
style
right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com